Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-2/neu peptide vaccine in advanced HER2+ breast cancer
NCT01729884Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Dec 2012
- Primary completion
- Jun 2013
- Countries
- 1
01
Overview
Phase 2, open-label trial of HER-2/neu peptide vaccine in breast cancer, sponsored by University of Washington. Started Dec 2012; status: terminated.
02
Drugs
HER-2/neu peptide vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01729884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01729884.